Associated Genetic Biomarkers
NCI Definition: A glioblastoma that arises de novo. It is more commonly seen in older patients. Mutations in IDH1 or IDH2 genes are not present. 
There are 6 clinical trials for glioblastoma, IDH-wildtype, of which 6 are open and 0 are completed or closed. Of the trials that contain glioblastoma, IDH-wildtype as an inclusion criterion, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open).
TERT and EGFR are the most frequent gene inclusion criteria for glioblastoma, IDH-wildtype clinical trials .
Bevacizumab, gs5745, and incagn01876 are the most common interventions in glioblastoma, IDH-wildtype clinical trials.
Significant Genes in Glioblastoma, IDH-Wildtype
EGFR is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, IDH-wildtype, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and glioblastoma, IDH-wildtype as inclusion criteria, 1 is phase 2 (1 open) .
TERT is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, IDH-wildtype, of which 2 are open and 0 are closed. Of the trials that contain TERT status and glioblastoma, IDH-wildtype as inclusion criteria, 2 are phase 2 (2 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.